Objective: The German KIMS Database is a national surveillance study for evaluation of efficacy and safety of growth hormone (GH) replacement therapy in adults with GH deficiency (GHD) in clinical practice.
Patients: The analysis was performed using data of 1425 consecutively documented adult patients (777 men, 648 women) with GHD enrolled in KIMS Germany. The present report examined baseline and long term data (>48 months, range: 48161 month) from a subset of 780 of these patients (420 men, 360 women) with GH deficiency aged 2075 (median 44) years. Patients have been assigned to sex and age-related groups (2039, 4059 and 6079 years). Patients were examined for serum IGF-1, blood glucose and lipid profile at baseline and at last visit. Furthermore QoL-AGHDA score has been determined for quality of live assessment. Most of the patients required additional pituitary replacement and were on optimal doses at recruitment.
Results: The IGF-1 and IGF-1 SDS-levels increased in all groups significantly (P<0.001). After GH therapy serum total cholesterol and low-density lipoprotein (LDL) decreased in males (Δ −0.2 mg/dl, P<0.005) and females (Δ −0.2 mg/dl, P<0.005) significantly. Blood glucose increased from 4.7 to 4.9 mmol/l (P<0.01) and in 15 patients the development of diabetes has been observed. The QoL-AGHDA score improved from 8 to 3 (P<0.001) in all groups significantly. Moreover we detected no influence of seasons on quality of live assessment. During the treatment recurrences of pituitary tumors n=44 (5.6%) or further neoplasia n=23 (2.9%) have been observed.
Conclusion: Therefore, these observational data showed significant long-term efficacy of adult GH replacement therapy on IGF-1, lipid profile as well as quality of life.
03 - 07 May 2008
European Society of Endocrinology